Horizon Discovery (Horizon) today announced it has begun a screening project with a ground-breaking U.S. cancer start-up; Prolexys Pharmaceuticals (Prolexys), relating to its X-MAN™ technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize key steps of the ‘targeted’ drug development process, and thus accelerate and economize the burgeoning field of ‘personalised’ medicine.
The agreements cover the screening of Prolexys lead compounds on a wide panel of genotypes. The approach should enable Prolexys to: (a) understand how selective their compounds are for the intended target versus off-target effects and; (b) to predict responsive patient types.
“Dr Chris Torrance, CEO of Horizon says “it has always been our aim combine our novel patient-relevant cancer models with exciting new start-up technologies and we hope to build a long and productive relationship with Prolexys”.
Prolexys will pay Horizon undisclosed fees during the term of the agreement. Work between the parties will begin in December 2008.